A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a Focus on Patients with Infections Due to Methicillin-resistant Staphylococcus aureus
- Conditions
- Complicated Gram-positive skin and skin structure infections with a focus on patients with infections due to methicillin-resistant Staphylococcus aureusMedDRA version: 6.1Level: HLTClassification code 10040788
- Registration Number
- EUCTR2004-002914-12-IT
- Lead Sponsor
- THERAVANCE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 750
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method